.: ORİJİNAL ARAŞTIRMA
Son Dönem Böbrek Yetersizliğinde Aterojenite ve Asimetrik Dimetilarjininin Yeri: Prospektif Gözlemsel Bir Çalışma
Atherogenicity in the End Stage Renal Disease and the Role of Asymetric Dimethylarginine: A Prospective Observational Study
Turkiye Klinikleri J Intern Med. 2023;8(2):58-67
doi: 10.5336/intermed.2022-93688
Makale Dili: TR
Tam Metin
ÖZET
Amaç: Bu çalışmanın amacı, son dönem böbrek yetersizliği olan hastalarda asimetrik dimetilarjinin (ADMA) düzeyleri ile ateroskleroz gelişimi arasındaki ilişkinin incelenmesidir. Gereç ve Yöntemler: Prospektif, gözlemsel ve kohort bir araştırma olarak planlanan bu çalışmaya 31 hemodiyaliz (HD), 28 periton diyalizi (PD) tedavisi alan ve 25 prediyaliz hastası dâhil edilmiştir. Her üç grubun ADMA, karotis arter intima-media kalınlığı, interlökin-6 (IL-6), interselüler adezyon molekülü-1 ve vasküler adezyon molekülü-1 düzeyleri ölçüldü. Öncelikle henüz diyaliz tedavisi başlanmamış son dönem kronik böbrek hastalığı olan hasta grubu ile diyaliz tedavisi uygulanan hastalar ADMA düzeyleri ve ADMA ile ateroskleroz göstergeleri arasında ilişki açısından karşılaştırıldı. Sonra HD veya PD tedavisi gören hastalar da ADMA düzeyleri ve ateroskleroz göstergeleri açısından karşılaştırıldı. Bulgular: Renal replasman tedavisi almayan prediyaliz grubu hastalarına kıyasla renal replasman tedavisi alan hastalarda karotis arter intima-media kalınlığı (p=0,016) ve IL-6 (p=0,009) düzeylerinin anlamlı olarak daha yüksek olduğu saptandı. PD uygulanan hastaların ADMA düzeylerinin HD uygulanan hastalara göre 0,1 µmol/L düşük olduğu saptandı, ancak bu fark istatistiksel olarak anlamlı değildi (p>0,05). ADMA ile karotis arter intima-media kalınlığı (r=0,371; p=0,001) ve IL-6 düzeyleri (r=0,240; p=0,035) arasında pozitif yönlü korelasyon olduğu saptandı. Karotis intima media kalınlığı ile IL-6 (r=0,321; p=0,004) ve serum kreatinin (r=0,377; p=0,015) düzeyleri arasında pozitif yönlü korelasyon olduğu saptandı. Sonuç: Bu çalışmada, son dönem böbrek yetersizliği gelişmiş hastalarda ateroskleroz gelişiminde geleneksel ateroskleroz risk faktörlerinin yanı sıra artmış ADMA düzeyi ve inflamasyon artışı gibi yeni risk faktörlerinin etkili olduğu saptanmıştır.
Anahtar Kelimeler: Asimetrik dimetilarjinin; ateroskleroz; nitrik oksit; son dönem böbrek hastalığı
Amaç: Bu çalışmanın amacı, son dönem böbrek yetersizliği olan hastalarda asimetrik dimetilarjinin (ADMA) düzeyleri ile ateroskleroz gelişimi arasındaki ilişkinin incelenmesidir. Gereç ve Yöntemler: Prospektif, gözlemsel ve kohort bir araştırma olarak planlanan bu çalışmaya 31 hemodiyaliz (HD), 28 periton diyalizi (PD) tedavisi alan ve 25 prediyaliz hastası dâhil edilmiştir. Her üç grubun ADMA, karotis arter intima-media kalınlığı, interlökin-6 (IL-6), interselüler adezyon molekülü-1 ve vasküler adezyon molekülü-1 düzeyleri ölçüldü. Öncelikle henüz diyaliz tedavisi başlanmamış son dönem kronik böbrek hastalığı olan hasta grubu ile diyaliz tedavisi uygulanan hastalar ADMA düzeyleri ve ADMA ile ateroskleroz göstergeleri arasında ilişki açısından karşılaştırıldı. Sonra HD veya PD tedavisi gören hastalar da ADMA düzeyleri ve ateroskleroz göstergeleri açısından karşılaştırıldı. Bulgular: Renal replasman tedavisi almayan prediyaliz grubu hastalarına kıyasla renal replasman tedavisi alan hastalarda karotis arter intima-media kalınlığı (p=0,016) ve IL-6 (p=0,009) düzeylerinin anlamlı olarak daha yüksek olduğu saptandı. PD uygulanan hastaların ADMA düzeylerinin HD uygulanan hastalara göre 0,1 µmol/L düşük olduğu saptandı, ancak bu fark istatistiksel olarak anlamlı değildi (p>0,05). ADMA ile karotis arter intima-media kalınlığı (r=0,371; p=0,001) ve IL-6 düzeyleri (r=0,240; p=0,035) arasında pozitif yönlü korelasyon olduğu saptandı. Karotis intima media kalınlığı ile IL-6 (r=0,321; p=0,004) ve serum kreatinin (r=0,377; p=0,015) düzeyleri arasında pozitif yönlü korelasyon olduğu saptandı. Sonuç: Bu çalışmada, son dönem böbrek yetersizliği gelişmiş hastalarda ateroskleroz gelişiminde geleneksel ateroskleroz risk faktörlerinin yanı sıra artmış ADMA düzeyi ve inflamasyon artışı gibi yeni risk faktörlerinin etkili olduğu saptanmıştır.
Anahtar Kelimeler: Asimetrik dimetilarjinin; ateroskleroz; nitrik oksit; son dönem böbrek hastalığı
ABSTRACT
Objective: The aim of this study is to investigate the relationship between asymmetric dimethylarginine (ADMA) levels and the development of atherosclerosis in patients with end-stage renal disease. Material and Methods: This study, which was planned as a prospective, observational and cohort study, included 31 hemodialysis (HD), 28 peritoneal dialysis (PD) and 25 predialysis patients. ADMA, carotid artery intima-media thickness, interleukin-6 (IL-6), intercellular adhesion molecule 1 and vascular cell adhesion molecule 1 levels were measured in all three groups. First of all, the patients with endstage chronic kidney disease who have not started dialysis treatment and the patients who received dialysis treatment were compared in terms of ADMA levels and the relationship between ADMA levels and atherosclerosis indicators. Then, patients receiving HD or PD were compared in terms of ADMA levels and atherosclerosis indicators. Results: Carotid artery intima-media thickness (p=0.016) and IL-6 (p=0.009) levels were found to be significantly higher in patients who received renal replacement therapy compared to patients in the predialysis group who did not receive renal replacement therapy. ADMA levels of the patients who underwent PD were found to be 0.1 µmol/L lower than the patients who underwent HD, but this difference was not statistically significant (p>0.05). A positive correlation was found between ADMA and carotid artery intima-media thickness (r=0.371; p=0.001) and IL-6 levels (r=0.240; p=0.035). A positive correlation was found between carotid intima-media thickness and IL-6 (r=0.321; p=0.004) and serum creatinine values (r=0.377; p=0.015). Conclusion: In this study, it was determined that in addition to traditional atherosclerosis risk factors, new risk factors such as increased ADMA level and increased inflammation were effective in the development of atherosclerosis in patients with end-stage renal disease.
Keywords: Asymmetric dimethylarginine; atherosclerosis; nitric oxide; end-stage renal disease
Objective: The aim of this study is to investigate the relationship between asymmetric dimethylarginine (ADMA) levels and the development of atherosclerosis in patients with end-stage renal disease. Material and Methods: This study, which was planned as a prospective, observational and cohort study, included 31 hemodialysis (HD), 28 peritoneal dialysis (PD) and 25 predialysis patients. ADMA, carotid artery intima-media thickness, interleukin-6 (IL-6), intercellular adhesion molecule 1 and vascular cell adhesion molecule 1 levels were measured in all three groups. First of all, the patients with endstage chronic kidney disease who have not started dialysis treatment and the patients who received dialysis treatment were compared in terms of ADMA levels and the relationship between ADMA levels and atherosclerosis indicators. Then, patients receiving HD or PD were compared in terms of ADMA levels and atherosclerosis indicators. Results: Carotid artery intima-media thickness (p=0.016) and IL-6 (p=0.009) levels were found to be significantly higher in patients who received renal replacement therapy compared to patients in the predialysis group who did not receive renal replacement therapy. ADMA levels of the patients who underwent PD were found to be 0.1 µmol/L lower than the patients who underwent HD, but this difference was not statistically significant (p>0.05). A positive correlation was found between ADMA and carotid artery intima-media thickness (r=0.371; p=0.001) and IL-6 levels (r=0.240; p=0.035). A positive correlation was found between carotid intima-media thickness and IL-6 (r=0.321; p=0.004) and serum creatinine values (r=0.377; p=0.015). Conclusion: In this study, it was determined that in addition to traditional atherosclerosis risk factors, new risk factors such as increased ADMA level and increased inflammation were effective in the development of atherosclerosis in patients with end-stage renal disease.
Keywords: Asymmetric dimethylarginine; atherosclerosis; nitric oxide; end-stage renal disease
REFERANSLAR:
- USRDS [Internet]. [Cited: Aug 3, 2022]. Annual Data Report. Available from: [Link]
- De Nicola L, Zoccali C. Chronic kidney disease prevalence in the general population: heterogeneity and concerns. Nephrol Dial Transplant. 2016;31(3):331-5. [Crossref] [PubMed]
- Süleymanlar G, Ateş K, Seyahi N, Koçyiğit İ. Türkiye'de Nefroloji, Diyaliz ve Transplantasyon. Ankara: Miki Matbaacılık; 2021. [Link]
- Provenzano M, Coppolino G, Faga T, Garofalo C, Serra R, Andreucci M. Epidemiology of cardiovascular risk in chronic kidney disease patients: the real silent killer. Rev Cardiovasc Med. 2019;20(4):209-20. [Crossref] [PubMed]
- Iwai T, Kataoka Y, Otsuka F, Asaumi Y, Nicholls SJ, Noguchi T, et al. Chronic kidney disease and coronary atherosclerosis: evidences from intravascular imaging. Expert Rev Cardiovasc Ther. 2019;17(10):707-16. [Crossref] [PubMed]
- Wojtaszek E, Oldakowska-Jedynak U, Kwiatkowska M, Glogowski T, Malyszko J. Uremic toxins, oxidative stress, atherosclerosis in chronic kidney disease, and kidney transplantation. Oxid Med Cell Longev. 2021;2021:6651367. [Crossref] [PubMed] [PMC]
- Laffin LJ, Bakris GL. Intersection between chronic kidney disease and cardiovascular disease. Curr Cardiol Rep. 2021;23:117. [Crossref] [PubMed]
- Kendrick J, Chonchol MB. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol. 2008;4(12):672-81. [Crossref] [PubMed]
- Ashokachakkaravarthy K, Rajappa M, Parameswaran S, Satheesh S, Priyadarshini G, Mohan Raj PS, et al. Asymmetric dimethylarginine and angiopoietin-like protein-2 are independent predictors of cardiovascular risk in pre-dialysis non-diabetic chronic kidney disease patients. Int Urol Nephrol. 2020;52(7):1321-8. [Crossref] [PubMed]
- Alpoim PN, Sousa LP, Mota AP, Rios DR, Dusse LM. Asymmetric Dimethylarginine (ADMA) in cardiovascular and renal disease. Clin Chim Acta. 2015 ;440:36-9. [Crossref] [PubMed]
- Sitar ME. Asymmetric dimethylarginine and its relation as a biomarker in nephrologic diseases. Biomark Insights. 2016;11:131-7. [Crossref] [PubMed] [PMC]
- Liu X, Xu X, Shang R, Chen Y. Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease. Nitric Oxide. 2018;78:113-20. [Crossref] [PubMed] [PMC]
- Ye J, Dai Y, Mao H, Zheng W, Zhang J. Prognostic value of asymmetric dimethylarginine in patients with coronary artery disease: a meta-analysis. Nitric Oxide. 2021;109-110:50-6. [Crossref] [PubMed]
- Shafi T, Hostetter TH, Meyer TW, Hwang S, Hai X, Melamed ML, et al. Serum asymmetric and symmetric dimethylarginine and morbidity and mortality in hemodialysis patients. Am J Kidney Dis. 2017;70(1):48-58. [Crossref] [PubMed] [PMC]
- Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502. [Crossref] [PubMed]
- Zhou S, Zhu Q, Li X, Chen C, Liu J, Ye Y, et al. Asymmetric dimethylarginine and all-cause mortality: a systematic review and meta-analysis. Sci Rep. 2017;7:44692. [Crossref] [PubMed] [PMC]
- Bentli R, Taskapan H, Taskapan MC, Dogan A. Serum asymmetric-dimethylarginine, apelin and NT-pro BNP levels in dialysis patients. Niger J Clin Pract. 2020;23(11):1542-7. [Crossref] [PubMed]
- Jacobi J, Tsao PS. Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review. Am J Nephrol. 2008;28(2):224-37. [Crossref] [PubMed] [PMC]
- Uzun H, Konukoglu D, Besler M, Erdenen F, Sezgin C, Muderrisoglu C. The effects of renal replacement therapy on plasma, asymmetric dimethylarginine, nitric oxide and C-reactive protein levels. Clin Invest Med. 2008;31(1):E1-7. [Crossref] [PubMed]
- Paul J, Dasgupta S, Ghosh MK. Carotid artery intima media thickness as a surrogate marker of atherosclerosis in patient with chronic renal failure on hemodialysis. N Am J Med Sci. 2012;4(2):77-80. [Crossref] [PubMed] [PMC]
- Polak JF, O'Leary DH. Carotid intima-media thickness as surrogate for and predictor of CVD. Glob Heart. 2016;11(3):295-312.e3. [Crossref] [PubMed]
- Liu D, Du C, Shao W, Ma G. Diagnostic role of carotid intima-media thickness for coronary artery disease: a meta-analysis. Biomed Res Int. 2020;2020:9879463. [Crossref] [PubMed] [PMC]
- Asicioglu E, Velioglu A, Arikan H, Koc M, Tuglular S, Ozener C. Baseline carotid intima-media thickness is associated with cardiovascular morbidity and mortality in peritoneal dialysis patients. Ther Apher Dial. 2021;25(6):962-9. [Crossref] [PubMed]
- Riccioni G, Scotti L, D'Orazio N, Gallina S, Speziale G, Speranza L, et al. ADMA/SDMA in elderly subjects with asymptomatic carotid atherosclerosis: values and site-specific association. Int J Mol Sci. 2014;15(4):6391-8. [Crossref] [PubMed] [PMC]
- Wang F, Xiong R, Feng S, Lu X, Li H, Wang S. Association of circulating levels of ADMA with carotid intima-media thickness in patients with ckd: a systematic review and meta-analysis. Kidney Blood Press Res. 2018;43(1):25-33. [Crossref] [PubMed]
- Attalah MF, Adel LA, Fahmy DE. Diagnostic and prognostic values of adhesion molecules VCAM-1, ICAM-1 and C-reactive protein in Egyptian patients with chronic kidney disease. Egypt J Immunol. 2011;18(2):59-66. [PubMed]
- Papagianni A, Dovas S, Bantis C, Belechri AM, Kalovoulos M, Dimitriadis C, et al. Carotid atherosclerosis and endothelial cell adhesion molecules as predictors of long-term outcome in chronic hemodialysis patients. Am J Nephrol. 2008;28(2):265-74. [Crossref] [PubMed]
.: İşlem Listesi